Patents by Inventor Jay Parthiban Lakshman
Jay Parthiban Lakshman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9011833Abstract: The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy.Type: GrantFiled: October 7, 2011Date of Patent: April 21, 2015Assignee: Novartis AGInventors: Sudhakar Devidasrao Garad, Anasuya Ashok Ghosh, Jay Parthiban Lakshman, Lipa Shah, Radha Vippagunta
-
Publication number: 20140323495Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.Type: ApplicationFiled: July 15, 2014Publication date: October 30, 2014Applicant: NOVARTIS AGInventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
-
Publication number: 20140287040Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Applicant: Novartis AGInventors: Yatindra Joshi, James Kowalski, Jay Parthiban Lakshman, Alan Edward Royce, Wei-Qin Tong, Madhav Vasanthavada
-
Publication number: 20140205663Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.Type: ApplicationFiled: March 27, 2014Publication date: July 24, 2014Applicant: Novartis AGInventors: James Kowalski, Jay Parthiban LakShman, Arun P. Patel
-
Publication number: 20130225598Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-pheny]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.Type: ApplicationFiled: April 17, 2013Publication date: August 29, 2013Applicant: Novartis AGInventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
-
Publication number: 20130190229Abstract: The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy.Type: ApplicationFiled: October 7, 2011Publication date: July 25, 2013Inventors: Sudhakar Devidasrao Garad, Anasuya Ashok Ghosh, Jay Parthiban Lakshman, Lipa Shah, Radha Vippagunta
-
Publication number: 20130052239Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.Type: ApplicationFiled: September 4, 2012Publication date: February 28, 2013Inventors: Yatindra Joshi, James Kowalski, Jay Parthiban Lakshman, Alan Edward Royce, Wei-Qin Tong, Madhav Vasanthavada
-
Publication number: 20130022672Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of lmatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.Type: ApplicationFiled: September 24, 2012Publication date: January 24, 2013Applicant: NOVARTIS AGInventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
-
Publication number: 20120294939Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.Type: ApplicationFiled: July 31, 2012Publication date: November 22, 2012Inventors: James Kowalski, Jay Parthiban Lakshman, Arun P. Patal
-
Publication number: 20110236479Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.Type: ApplicationFiled: June 6, 2011Publication date: September 29, 2011Inventors: James Kowalski, Jay Parthiban Lakshman, Arun P. Patel
-
Publication number: 20110045062Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.Type: ApplicationFiled: November 4, 2010Publication date: February 24, 2011Inventors: Yatindra Joshi, James Kowalski, Jay Parthiban Lakshman, Alan Edward Royce, Wei-Qin Tong, Madhav Vasanthavada
-
Publication number: 20100233253Abstract: An extended release gastro-retentive drug delivery system of Valsartan. The drug delivery system contains a release portion containing the Valsartan, a gastro-retentive portion for retaining the drug delivery system in the stomach and an optional secondary portion for delivering a secondary pulse of Valsartan. In another embodiment, there is provided a swellable unfolding membrane comprising Valsartan for sustained administration of Valsartan to the upper GI tract of a patient.Type: ApplicationFiled: August 29, 2007Publication date: September 16, 2010Applicant: Novartis AGInventors: Nikhil Javant Kavimandan, Jay Parthiban Lakshman, Arnol Singh Matharu, Joerg Ogorka, Alan Edward Royce, Noel Raj Teelucksingh
-
Publication number: 20100178336Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N--[4-methyl-3-( 4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.Type: ApplicationFiled: June 5, 2008Publication date: July 15, 2010Applicant: NOVARTIS AGInventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
-
Publication number: 20100015225Abstract: Solid dispersion comprising (4R)-4-[N?-methyl-N?-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N—[(R)-epsilon-caprolactam-3-yl]-amide or a pharmaceutically acceptable salt or solvate thereof and a carrier. Pharmaceutical compositions comprising such solid dispersion are useful to treat patients who have functional motility disorders of the viscera, especially irritable bowel syndrome or functional dyspepsia, or urinary bladder disorders, especially urinary incontinence.Type: ApplicationFiled: December 20, 2007Publication date: January 21, 2010Inventors: Anke Diederich, Carsten Timpe, Angelika Ries, Isabel Ottinger, Irene Mueller, Michael Herbig, Helmut Schuetz, Jay Parthiban Lakshman, Oskar Kalb
-
Publication number: 20090148522Abstract: A process for using a heated roller compactor to prepare melt granulated composition of a therapeutic compound, especially a poorly compressible and/or moisture sensitive therapeutic compound, with a granulation excipient.Type: ApplicationFiled: May 3, 2007Publication date: June 11, 2009Inventors: James Kowalski, Jay Parthiban Lakshman, Abu T.M. Serajuddin, Wei-Qin Tong
-
Publication number: 20080280999Abstract: A process for making a solid oral dosage form that has a therapeutic compound (e.g., a poorly soluble and/or poorly compactible therapeutic compound) and a polymer. The process is accomplished by the use of an extruder. A transient plasticizer, e.g., a liquefied gas such as supercritical carbon dioxide, is added to facilitate processing of the materials. The transient plasticizer can serve to lower the viscosity of the mixture being processes and/or enhance the solubility of the therapeutic compound.Type: ApplicationFiled: November 7, 2006Publication date: November 13, 2008Applicant: NOVARTIS AGInventor: Jay Parthiban Lakshman
-
Publication number: 20080226731Abstract: Sustained release pharmaceutical compositions that contain imatinib or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions further contain a release retardant, for example a water soluble, a water swellable and/or a water insoluble polymer. The present invention also features a particularly useful process of making such sustained release pharmaceutical compositions by using an extruder.Type: ApplicationFiled: May 8, 2006Publication date: September 18, 2008Inventors: Madhav Vasanthavada, Jay Parthiban Lakshman, Wei-Qin Tong, Abu T.M. Serajuddin
-
Publication number: 20080227825Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.Type: ApplicationFiled: September 25, 2006Publication date: September 18, 2008Inventors: Yatindra Joshi, James Kowalski, Jay Parthiban Lakshman, Alan Edward Royce, Wei-Qin Tong, Madhav Vasanthavada
-
Publication number: 20080193529Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with a glitazone and specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.Type: ApplicationFiled: June 8, 2006Publication date: August 14, 2008Inventors: James Kowalski, Jay Parthiban Lakshman, Arun Patel
-
Publication number: 20080038341Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.Type: ApplicationFiled: January 17, 2005Publication date: February 14, 2008Inventors: James Kowalski, Jay Parthiban Lakshman, Arun P. Patel